Evonik Evonik

X
menu

    Market Place

    Market Place

    Post Enquiry

    Post Enquiry
    menu

    Find the latest Drugs in Development and Pipeline Prospector News of Ripple Therapeutics.

    Client Virtual Booth

    RIPPLE THERAPEUTICS

    EVENTS

    • Webinars & Exhibitions

    PRESENTATION(s)

    VIDEO(s)

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Contact SupplierContact Supplier
    Google MapGoogle Map
    Full View ScreenFull View Screen
    Send me more info on How To Grow My Bussiness Digitally?
    Ripple Therapeutics
    Canada Flag
    Country
    Country
    Canada
    Address
    Address
    MaRS Center, South Tower 101 College Street, Suite 300 Toronto, ON, M5G 1L7
    Telephone
    Telephone
    (416) 673-8170
    Client Email
    Email
    enquiries@pharmacompass.com
    Client Website
    Website
    https://www.rippletherapeutics.com/
    Linkedin
    Linkedin
    https://www.linkedin.com/company/ripple-therapeutics/?originalSubdomain=ca
    Twitter
    Twitter

    Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

    Full View ScreenFull Screen View
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation

    Details:

    The licensing deal with TOI includes a significant upfront payment, sizeable clinical and regulatory milestones and double-digit royalties. As part of the Licensing Agreement, TOI will also manage and finance the Phase III pivotal trials for IBE-814 IVT.


    Lead Product(s): Dexamethasone

    Therapeutic Area: Ophthalmology Product Name: IBE-814 IVT

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Laboratoires Thea

    Deal Size: Undisclosed Upfront Cash: Undisclosed

    Deal Type: Licensing Agreement December 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    • Deals
    Virtual Booth Upload your Marketing & Sales content on your company Virtual Booth, click HERE

    Ripple Therapeutics Secures Licensing Agreement and Series A Financing led by Théa Open Innovation

    Details:

    Along with a Series A The licensing deal with TOI includes a significant upfront payment, sizeable clinical and regulatory milestones and double-digit royalties. As part of the Licensing Agreement, TOI will also manage and finance the Phase III pivotal trials for IBE-814 IVT.


    Lead Product(s): Dexamethasone

    Therapeutic Area: Ophthalmology Product Name: IBE-814 IVT

    Highest Development Status: Phase IIProduct Type: Small molecule

    Partner/Sponsor/Collaborator: Laboratoires Thea

    Deal Size: $22.0 million Upfront Cash: Undisclosed

    Deal Type: Series A Financing December 15, 2020

    ASK
    US
    PHARMACOMPASS
    Upload
    your Marketing & Sales content
    Full Screen ViewFULL SCREEN VIEW Click here to open all results in a new tab [this preview display 10 results]
    Ask Us for Pharmaceutical Supplier and Partner
    Ask Us, Find A Supplier / Partner
    No Commissions, No Strings Attached, Get Connected for FREE

    What are you looking for?

    How can we help you?

    The request can't be empty

    Please read our Privacy Policy carefully

    You must agree to the privacy policy

    The name can't be empty
    The company can't be empty.
    The email can't be empty Please enter a valid email.
    The mobile can't be empty
    euroapi-2024-05-06

    Access Virtual Booth

    Contact Supplier

    Send me more info on How To Grow My Business Digitally?
    Post Enquiry
    POST ENQUIRY

    Market Place

    Market Place

    PharmaCompass

    Home

    Market Place

    Menu

    Post Enquiry

    Post Enquiry

    Market Place

    Market Place

    Search